Drug intelligence / Profile preview

Ambitasol

Development stage: Unknown
Lead developer: Pharmex
Modality: Small Molecules
Administration: Topical

Overview

Ambitasol is a topical antiseptic solution commercialized by the Greek specialty pharmaceutical company Pharmex and manufactured by Cana Laboratories, a subsidiary of Cosmos Health. Marketed in 1-liter containers, it is utilized for disinfection and infection prevention. While the specific active pharmaceutical ingredient is not explicitly defined in the provided clinical context, the product is positioned within a portfolio of medicinal antiseptics and dermocosmetics intended for clinical and general hygiene applications.

Brand names: Ambitasol

Beyond the preview

Go deeper on Ambitasol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ambitasol.

Explore the full profile